Our Mission

  • At Mountain Group, we partner with entrepreneurs and businesses developing transformational technologies that improve the lives of others.
  • Our balance of scientific, operational and investment expertise allows us to maintain an active role in helping lead our companies from discovery to commercialization.
  • We take a collaborative approach to improving the healthcare ecosystem and regularly utilize our value-added network of like-minded investors and industry leaders.
Learn More

Our Focus

We prefer to invest in early-stage companies with quality leadership, quantifiable development risk, and novel innovations predominantly in the Life Sciences, Animal Health and Technology sectors.

Life Sciences

MedTech, Diagnostics, Opportunistic Drug Development

Animal Health

Pet and Livestock Health,
Protein Production

Disruptive Technologies

Clean Energy, Remote Monitoring,
Transformational Services

Learn More

Our Companies

Select Investments

castle biosciences
Fund: 2013, 2018
Sector: Life Sciences

Castle Biosciences is focused on developing and commercializing molecular diagnostics to aid health care professionals in assessing types and sub-types of tumors. Products focus on differentiating tumor types at the molecular level using various means of analyzing and comparing components of DNA.

angel eye health logo
Fund: 2018
Sector: Disruptive Technology

AngelEye Health has developed internet-based camera systems and educational and clinical communications software to transform neonatal care.

silicon ranch logo
Fund: 2013, 2018
Sector: Disruptive Technology

Silicon Ranch Corporation is a developer and operator of utility scale solar facilities that provides turn-key renewable energy solutions to industry and utility partners.

Fund: 2018
Sector: Life Sciences

Appello Pharmaceuticals is a preclinical-stage company focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease.

exubrion logo
Fund: 2018
Sector: Animal Health

Exubrion Therapeutics is developing a radiosynoviorthesis product to treat chronic osteoarthritis in dogs. The technology was originally developed for human use.

View Portfolio

Recent News

6/28/22

Mountain Group Partners Completes Fundraising on $128 Million MGP Venture Fund III

Read More
5/25/22

TARGAN Secures $35M Series C Financing Led by Mountain Group Partners and NovaQuest Capital Management to Commercialize Novel Vaccine Delivery System for Poultry Industry

Read More
4/28/22

MINDERA HEALTH™ LAUNCHES PILOT WITH NATIONAL HEALTH INSURANCE COMPANY TO IMPROVE MANAGEMENT OF MODERATE-TO-SEVERE PSORIASIS PATIENTS THROUGH PRECISION MEDICINE

Read More
View All News